SurModics implants intravitreal device:
This article was originally published in Clinica
SurModics says that its intravitreal drug-delivery implant for treating diabetic macular oedema (DMO) has been implanted successfully in the first patients of its US phase I trial of the device. I-vation, one of the drug delivery technologies that was acquired by SurModics in January 2005 in connection with its acquisition of InnoRx, could solve the problem of sustained delivery of various therapies in the eye, said the Eden Prairie, Minnesota firm. The implantwas easily inserted during a brief outpatient surgical procedure using local anaesthesia. Early follow-up has shown the implant to be well tolerated.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.